1st Trend line - ALRNThis is my first take on drawing a trend line for ALRN. Please provide comment and feedback. Thank you.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.25 USD
−15.73 M USD
0.00 USD
19.54 M
About Aileron Therapeutics, Inc.
Sector
CEO
Brian J. Windsor
Headquarters
Austin
Website
Founded
2001
FIGI
BBG002454KR1
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
ALRN Possible Bullish Breakout ALRN is Hot right now and posted big gains in After Hours Friday, we should see continued momentum and further upside
ALRN Weekend Data CatalystALRN had some weekend news. Will be interesting to see if it can break above a near-two-year resistance level. I didn't show it all the way back to November of 2018 but if you take the chart out further, you can see this level holding as resistance.
"Saturday, the company announced new positive cl
ALRN long swingThe price tested the trendline and the 50 day ma to close above the .23 fibonacci level and right on the 20 day EMA. Resistance at 1.38, first target of 1.48 second at 1.68
$ALRN Upside continuation targets Multiple upgrades post earnings
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company’s shares closed last Tuesday at $0.66.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 4
Recent insider buying Recent & repeated insider buying. Company expanding cancer trial with $PFE palbociclib & will report full dataset in Q2 2020. Trading below cash.
$ALRN Looking for a 1-2 dollar move.On a Beginning start of a TOP pattern this could be a dollar move and make a quick 50$+ depending on trade size of course.
TOP patterns are vary reliable but we are looking at the past and the Volume and float also. its looking good. lets see how this runs make sure
you add a stop lose to your chart
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALRN is 3.72 USD — it has decreased by −2.34% in the past 24 hours. Watch Aileron Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aileron Therapeutics, Inc. stocks are traded under the ticker ALRN.
ALRN stock has fallen by −3.85% compared to the previous week, the month change is a 13.64% rise, over the last year Aileron Therapeutics, Inc. has showed a 155.85% increase.
We've gathered analysts' opinions on Aileron Therapeutics, Inc. future price: according to them, ALRN price has a max estimate of 7.00 USD and a min estimate of 7.00 USD. Watch ALRN chart and read a more detailed Aileron Therapeutics, Inc. stock forecast: see what analysts think of Aileron Therapeutics, Inc. and suggest that you do with its stocks.
ALRN reached its all-time high on Oct 5, 2017 with the price of 309.60 USD, and its all-time low was 1.01 USD and was reached on Oct 31, 2023. View more price dynamics on ALRN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALRN stock is 4.07% volatile and has beta coefficient of 3.59. Track Aileron Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aileron Therapeutics, Inc. there?
Today Aileron Therapeutics, Inc. has the market capitalization of 83.20 M, it has increased by 10.90% over the last week.
Yes, you can track Aileron Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aileron Therapeutics, Inc. is going to release the next earnings report on Nov 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ALRN earnings for the last quarter are −0.45 USD per share, whereas the estimation was −0.31 USD resulting in a −47.25% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Aileron Therapeutics, Inc. earnings.
Aileron Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ALRN net income for the last quarter is −8.94 M USD, while the quarter before that showed −7.11 M USD of net income which accounts for −25.71% change. Track more Aileron Therapeutics, Inc. financial stats to get the full picture.
No, ALRN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 15.00 employees. See our rating of the largest employees — is Aileron Therapeutics, Inc. on this list?
Like other stocks, ALRN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aileron Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aileron Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aileron Therapeutics, Inc. stock shows the neutral signal. See more of Aileron Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.